Nicholas Fuggle, WCO IOF-ESCEO 2022: Understanding the Patient in the Management of Hand Osteoarthritis
We were delighted to talk with Dr. Nicholas Fuggle (the University of Southampton, Southampton, UK) around the unmet needs and the burden of hand osteoarthritis for patients and how patient outcomes can be improved in the future.
‘Management of hand osteoarthritis: what really matters for the patient’ was presented at WCO IOF-ESCEO 2022, 24-26 March, 2022
- What symptoms of hand osteoarthritis are most burdensome for patients? (0:40)
- What are the unmet needs in the management of hand osteoarthritis? (1:35)
- What patient factors should be considered when managing hand osteoarthritis? (2:25)
- What patient reported outcomes should be included in future clinical trials? (3:31)
Disclosures: Nicholas Fuggle has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the WCO IOF-ESCEO annual meeting 2022.
Share this Video
Related Videos In Rheumatic Diseases
Machine-learning models as predictors of fractures in osteoporosis: Giovanni Adami, WCO-IOF-ESCEO 2023
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!